Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 28, 2020 - Issue 4
Submit an article Journal homepage
159
Views
6
CrossRef citations to date
0
Altmetric
Letter To The Editor

Clinical Course of Preexisting Uveitis during Treatment of Lung Cancer with Durvalumab

Tessnim R. Ahmad1 School of Medicine, University of California, San Francisco, California, USA
, BS,
Thuy Doan2 F.I. Proctor Foundation, University of California, San Francisco, California, USA;3 Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, California, USAORCID Iconhttps://orcid.org/0000-0003-2733-8370
, MD, PhDORCID Icon,
John A. Gonzales2 F.I. Proctor Foundation, University of California, San Francisco, California, USA;3 Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, California, USAORCID Iconhttps://orcid.org/0000-0003-0558-9793
, MDORCID Icon,
Nisha R. Acharya2 F.I. Proctor Foundation, University of California, San Francisco, California, USA;3 Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
, MD, MS &
Edmund Tsui2 F.I. Proctor Foundation, University of California, San Francisco, California, USA;3 Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, California, USA;4 UCLA Stein Eye Institute, Los Angeles, California, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7532-9191
, MDORCID Icon
Pages 566-570 | Received 21 Jul 2019, Accepted 07 Oct 2019, Published online: 11 Nov 2019

REFERENCES

  • Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. doi:10.1016/j.ejca.2015.11.016.
  • Sun MM, Levinson RD, Filipowicz A, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm. March, 2019;1–11. doi:10.1080/09273948.2019.1577978.
  • Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123(11):1904–1911. doi:10.1002/cncr.30642.
  • Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168(2):121–130. doi:10.7326/M17-2073.
  • Highlights of Prescribing Information. Food and drug adminstration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761069s002lbl.pdf. Accessed June 23, 2019.
  • Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina (Philadelphia, Pa). 2018;38(6):1063–1078. doi:10.1097/IAE.0000000000002181.
  • Thomas M, Armenti ST, Ayres MB, Demirci H. Uveal effusion after immune checkpoint inhibitor therapy. JAMA Ophthalmol. 2018;136(5):553–556. doi:10.1001/jamaophthalmol.2018.0920.
  • Noble CW, Gangaputra SS, Thompson IA, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. April, 2019;1–6. doi:10.1080/09273948.2019.1583347.
  • Venkat AG, Arepalli S, Sharma S, et al. Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. Br J Ophthalmol. August, 2019. doi:10.1136/bjophthalmol-2019-314403.
  • Kennedy LC, Bhatia S, Thompson JA, Grivas P. Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J Natl Compr Canc Netw. 2019;17(6):750–757. doi:10.6004/jnccn.2019.7310.
  • Donia M, Pedersen M, Svane IM. Cancer immunotherapy in patients with preexisting autoimmune disorders. Semin Immunopathol. 2017;39(3):333–337. doi:10.1007/s00281-016-0595-8.
  • Diem S, Keller F, Rüesch R, et al. Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy? J Immunother. 2016;39(9):379–382. doi:10.1097/CJI.0000000000000143.
  • Chan SM, Hudson M, Weis E. Anterior and intermediate uveitis cases referred to a tertiary centre in Alberta. Can J Ophthalmol. 2007;42(6):860–864. doi:10.3129/i07-159.
  • Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768. doi:10.1200/JCO.2017.77.6385.
  • Tsui E, Gonzales JA. Retinal vasculitis associated with ipilimumab. Ocul Immunol Inflamm. July, 2019;1–3. doi:10.1080/09273948.2019.1610460.
  • Barreto M, Santos E, Ferreira R, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet. 2004;12(8):620–626. doi:10.1038/sj.ejhg.5201214.
  • Lee YH, Bae S-C, Kim J-H, Song GG. Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility. Z Rheumatol. 2015;74(3):230–239. doi:10.1007/s00393-014-1415-y.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.